{
  "id": "5e33904afbd6abf43b00005f",
  "type": "yesno",
  "question": "Does radiotherapy for Hodgkin disease increases risk for lung cancer?",
  "ideal_answer": "Yes, radiotherapy for Hodgkin disease is associated with increased risk for lung cancer.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/11830608",
    "http://www.ncbi.nlm.nih.gov/pubmed/2754447",
    "http://www.ncbi.nlm.nih.gov/pubmed/11045784",
    "http://www.ncbi.nlm.nih.gov/pubmed/23053567",
    "http://www.ncbi.nlm.nih.gov/pubmed/27913498",
    "http://www.ncbi.nlm.nih.gov/pubmed/25104066",
    "http://www.ncbi.nlm.nih.gov/pubmed/25025999",
    "http://www.ncbi.nlm.nih.gov/pubmed/7563187",
    "http://www.ncbi.nlm.nih.gov/pubmed/2981984",
    "http://www.ncbi.nlm.nih.gov/pubmed/25615851",
    "http://www.ncbi.nlm.nih.gov/pubmed/1428226",
    "http://www.ncbi.nlm.nih.gov/pubmed/26530956",
    "http://www.ncbi.nlm.nih.gov/pubmed/25754634"
  ],
  "snippets": [
    {
      "text": "Risks of lung, breast, and gastrointestinal (GI) cancers increase with higher radiation dose. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27913498",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: RT treatment, especially with doses higher than 42 Gy, and smoking increase the risk of SN after HL. In this series, LC patients with early stages had a shorter elapsed time from HL diagnosis and longer OS, therefore the role of LC screening in HL survivors should be prospectively evaluated and smoking cessation counseling ought to be a key aspect during follow-up.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26530956",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Long-term Hodgkin lymphoma (HL) survivors have an increased risk of late cardiac morbidity and secondary lung cancer after chemotherapy and mediastinal radiotherapy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25025999",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: Hodgkin lymphoma (HL) survivors have an increased risk of cardiovascular disease (CD), lung cancer, and breast cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25754634",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lung cancer (LC) represents the most common solid tumor in survivors of Hodgkin's disease (HD), and the assessment of the mutational status of oncogenic driver mutations in LC is now standard. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25615851",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: Hodgkin lymphoma (HL) survivors face an increased risk of treatment-related lung cancer. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25104066",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Increased risk of second lung cancer in Hodgkin's lymphoma survivors: a meta-analysis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23053567",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: Patients treated for Hodgkin's lymphoma (HL) have a higher risk of developing second lung cancer (SLC) compared with the general population. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23053567",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The pooled relative risk (RR) of SLC was 4.62 (95 % confidence interval [CI], 3.18-6.70], I (2) = 98 %), with a median absolute excess rate of 10.4 per 10,000 person-years. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23053567",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: The current meta-analysis provided a detailed estimate of the risk of SLC among HL survivors. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23053567",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS\n\nThe excess risk of lung cancer in Hodgkin's disease patients treated with radiotherapy is related to the radiation dose received by the affected area of the lung.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/7563187",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\n\nLung cancer is a frequent cause of death in patients cured of Hodgkin's disease, but the contributions of chemotherapy, radiotherapy, and smoking are not well described.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11830608",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS\n\nPast treatments with alkylating agents and radiation therapy for Hodgkin's disease were associated with an increased risk of lung cancer in a dose-dependent and additive fashion.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11830608",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\n\nSeveral studies have shown that survivors of Hodgkin's disease have increased risk of lung cancer, but the factors responsible for this excess risk are not well known.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/7563187",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE\n\nThis study was undertaken to investigate the effects of radiation dose, chemotherapy, and smoking on the risk of lung cancer following treatment of Hodgkin's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/7563187",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Increased risk of lung cancer, non-Hodgkin's lymphoma, and leukemia following Hodgkin's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2754447",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "It is recognized that survivors of Hodgkin's disease are at a substantially increased risk of lung cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/1428226",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The risk of lung and breast cancer is significantly increased after therapy for Hodgkin 's disease ( HD) , but there are few data that describe the molecular profiles of these tumors . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11045784",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Hodgkin lymphoma ( HL ) survivors have an increased risk of cardiovascular disease ( CD) , lung cancer , and breast cancer . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25754634",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nLung cancer is a frequent cause of death in patients cured of Hodgkin's disease, but the contributions of chemotherapy, radiotherapy, and smoking are not well described.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11830608",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS\nPast treatments with alkylating agents and radiation therapy for Hodgkin's disease were associated with an increased risk of lung cancer in a dose-dependent and additive fashion.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11830608",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lung cancer in Hodgkin's disease: association with previous radiotherapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2981984",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Twenty-eight (94%) of 30 patients developing metachronous lung cancer received supradiaphragmatic irradiation as primary therapy for HD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2981984",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The risk ratio for the development of lung cancer among HD patients was 5.6 times that expected in the general population.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2981984",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Seven cases of lung cancer were observed in patients with Hodgkin's disease (HD) since 1970.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2981984",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nSeveral studies have shown that survivors of Hodgkin's disease have increased risk of lung cancer, but the factors responsible for this excess risk are not well known.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/7563187",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The excess risk of lung cancer in Hodgkin's disease patients treated with radiotherapy is related to the radiation dose received by the affected area of the lung.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/7563187",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lung cancer is a frequent cause of death in patients cured of Hodgkin's disease, but the contributions of chemotherapy, radiotherapy, and smoking are not well described.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11830608",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Past treatments with alkylating agents and radiation therapy for Hodgkin's disease were associated with an increased risk of lung cancer in a dose-dependent and additive fashion.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11830608",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Several studies have shown that survivors of Hodgkin's disease have increased risk of lung cancer, but the factors responsible for this excess risk are not well known.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/7563187",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}